-
Study aim
-
Determine the effectiveness of midazolam in blood pressure control in patients presenting to the emergency department with a diagnosis of hypertensive crisis
-
Design
-
If the code in envelope A is patient with captopril and distilled water, if the code is B, it is a medication called Midazolam and a placebo of vitamin B, and if the code C is given, then Midazolam and Captopril will be prescribed.
-
Settings and conduct
-
This is a triple-blind clinical trial that will be performed on hypertensive patients referred to Emergency Hospital of Imam Hossein Shahroud Hospital.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: systolic or diastolic blood pressure above 180 on 110 mm Hg, the age group of 80-18 years, have the power to understand and sign an informed consent. Exclusion criteria: Acute left heart failure, Chronic renal failure, cardiovascular disease, History of stroke, History of myocardial infarction, Benzodiazepines consumed in the last week, Use muscle relaxants such as baclofen or anti-anxiety drugs, Other groups such as Zolpidem or Buspirone, Captopril susceptibility, Sensitivity to midazolam, Pregnant and lactating women, The occurrence of a critical condition, according to the doctor's opinion, requires the administration of a low blood pressure medication other than midazolam and captopril. Patients with a difference between the two arms are more than 15 mm Hg.
-
Intervention groups
-
This study is randomly divided into three groups of 43 people. The two main drug captopril sublingual orally (25 mg) and midazolam intravenous injection (1 mg) will take place. Two placebos will be used in this program, which includes oral pills of vitamin B instead of captopril and distilled water instead of midazolam. After obtaining informed consent, patients will be randomly divided into three groups according to the order of the envelope.
-
Main outcome variables
-
hypertension